Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease

Overview

Journal Neurol Res Int

Publisher Wiley

Specialty Neurology

Date 2011 Jul 19

PMID 21766020

Citations 26

Authors

Mahesh Kandasamy

Ralf Reilmann

Jurgen Winkler

Ulrich Bogdahn

Ludwig Aigner

Affiliations

Soon will be listed here.

Abstract

The neural stem cell niches possess the regenerative capacity to generate new functional neurons in the adult brain, suggesting the possibility of endogenous neuronal replacement after injury or disease. Huntington disease (HD) is a neurodegenerative disease and characterized by neuronal loss in the basal ganglia, leading to motor, cognitive, and psychological disabilities. Apparently, in order to make use of the neural stem cell niche as a therapeutic concept for repair strategies in HD, it is important to understand the cellular and molecular composition of the neural stem cell niche under such neurodegenerative conditions. This paper mainly discusses the current knowledge on the regulation of the hippocampal neural stem cell niche in the adult brain and by which mechanism it might be compromised in the case of HD.

Citing Articles

A collaborative network analysis for the interpretation of transcriptomics data in Huntington's disease.

Ozisik O, Kara N, Abbassi-Daloii T, Terezol M, Kuijper E, Queralt-Rosinach N Sci Rep. 2025; 15(1):1412.

PMID: 39789061 PMC: 11718016. DOI: 10.1038/s41598-025-85580-4.

The functional and structural changes in the hippocampus of COVID-19 patients.

Nouraeinejad A Acta Neurol Belg. 2023; 123(4):1247-1256.

PMID: 37226033 PMC: 10208918. DOI: 10.1007/s13760-023-02291-1.

Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.

Roshan S, Elangovan G, Gunaseelan D, Jayachandran S, Kandasamy M, Anusuyadevi M J Alzheimers Dis. 2023; 94(s1):S289-S308.

PMID: 36776051 PMC: 10473090. DOI: 10.3233/JAD-220831.

SARS-CoV-2-Mediated Neuropathogenesis, Deterioration of Hippocampal Neurogenesis and Dementia.

Radhakrishnan R, Kandasamy M Am J Alzheimers Dis Other Demen. 2022; 37:15333175221078418.

PMID: 35133907 PMC: 10581113. DOI: 10.1177/15333175221078418.

Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders.

Peters S, Wirkert E, Kuespert S, Heydn R, Johannesen S, Friedrich A Pharmaceutics. 2022; 14(1).

PMID: 35057094 PMC: 8780845. DOI: 10.3390/pharmaceutics14010200.

References

Van Raamsdonk J, Pearson J, Slow E, Hossain S, Leavitt B, Hayden M . Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci. 2005; 25(16):4169-80. PMC: 6724951. DOI: 10.1523/JNEUROSCI.0590-05.2005. View

Donovan M, Yazdani U, Norris R, Games D, German D, Eisch A . Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol. 2006; 495(1):70-83. DOI: 10.1002/cne.20840. View

Annes J, Munger J, Rifkin D . Making sense of latent TGFbeta activation. J Cell Sci. 2002; 116(Pt 2):217-24. DOI: 10.1242/jcs.00229. View

Mostert J, Koch M, Heerings M, Heersema D, De Keyser J . Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther. 2008; 14(2):153-64. PMC: 6494017. DOI: 10.1111/j.1527-3458.2008.00040.x. View

Wyss-Coray T . Tgf-Beta pathway as a potential target in neurodegeneration and Alzheimer's. Curr Alzheimer Res. 2006; 3(3):191-5. DOI: 10.2174/156720506777632916. View

Kassubek J, Gaus W, Landwehrmeyer G . Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2004; 62(3):523-4. DOI: 10.1212/wnl.62.3.523-a. View

Darsalia V, Heldmann U, Lindvall O, Kokaia Z . Stroke-induced neurogenesis in aged brain. Stroke. 2005; 36(8):1790-5. DOI: 10.1161/01.STR.0000173151.36031.be. View

Aberg N, Johansson I, Aberg M, Lind J, Johansson U, Cooper-Kuhn C . Peripheral administration of GH induces cell proliferation in the brain of adult hypophysectomized rats. J Endocrinol. 2009; 201(1):141-50. DOI: 10.1677/JOE-08-0495. View

Haque N, Isacson O . Antisense gene therapy for neurodegenerative disease?. Exp Neurol. 1997; 144(1):139-46. DOI: 10.1006/exnr.1996.6400. View

10.

Hoglinger G, Rizk P, Muriel M, Duyckaerts C, Oertel W, Caille I . Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci. 2004; 7(7):726-35. DOI: 10.1038/nn1265. View

11.

Snyder E, Yoon C, Flax J, Macklis J . Multipotent neural precursors can differentiate toward replacement of neurons undergoing targeted apoptotic degeneration in adult mouse neocortex. Proc Natl Acad Sci U S A. 1997; 94(21):11663-8. PMC: 23575. DOI: 10.1073/pnas.94.21.11663. View

12.

Bode F, Stephan M, Suhling H, Pabst R, Straub R, Raber K . Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet. 2008; 17(17):2595-609. DOI: 10.1093/hmg/ddn159. View

13.

Deng W, Aimone J, Gage F . New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?. Nat Rev Neurosci. 2010; 11(5):339-50. PMC: 2886712. DOI: 10.1038/nrn2822. View

14.

Mathieu P, Piantanida A, Pitossi F . Chronic expression of transforming growth factor-beta enhances adult neurogenesis. Neuroimmunomodulation. 2010; 17(3):200-1. DOI: 10.1159/000258723. View

15.

Shulman J, Shulman L, Weiner W, Feany M . From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease. Curr Opin Neurol. 2003; 16(4):443-9. DOI: 10.1097/01.wco.0000084220.82329.60. View

16.

Chesselet M, Delfs J, Mackenzie L . Dopamine control of gene expression in basal ganglia nuclei: striatal and nonstriatal mechanisms. Adv Pharmacol. 1997; 42:674-7. DOI: 10.1016/s1054-3589(08)60838-8. View

17.

Schlingensiepen K, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B . Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2005; 17(1-2):129-39. DOI: 10.1016/j.cytogfr.2005.09.002. View

18.

Massague J, Gomis R . The logic of TGFbeta signaling. FEBS Lett. 2006; 580(12):2811-20. DOI: 10.1016/j.febslet.2006.04.033. View

19.

Song H, Kempermann G, Overstreet Wadiche L, Zhao C, Schinder A, Bischofberger J . New neurons in the adult mammalian brain: synaptogenesis and functional integration. J Neurosci. 2005; 25(45):10366-8. PMC: 6725835. DOI: 10.1523/JNEUROSCI.3452-05.2005. View

20.

Jason G, Suchowersky O, Pajurkova E, Graham L, Klimek M, GARBER A . Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset. Arch Neurol. 1997; 54(9):1081-8. DOI: 10.1001/archneur.1997.00550210019008. View